Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
Open PDF
| Stock | Race Oncology Ltd (RAC.ASX) |
|---|---|
| Release Time | 25 Jun 2026, 8:55 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Race Oncology Initiates HARNESS-1 Lung Cancer Trial
Key Points
- First patient treated in HARNESS-1 Phase 1 RC220 trial
- RC220 assessed with osimertinib for EGFR-mutant NSCLC
- No adverse events observed in initial dosing
Full Summary
Race Oncology Ltd. has announced the initiation of the HARNESS-1 Phase 1 clinical trial for RC220, a potential treatment for EGFR-mutant non-small cell lung cancer (NSCLC). The trial, which began with the treatment of the first patient, is evaluating RC220 in combination with osimertinib, a standard-of-care tyrosine kinase inhibitor. The first patient was treated at Monash Health, and no adverse events were observed. The trial aims to address the challenge of osimertinib resistance in EGFR-mutant NSCLC patients. The study will progress through dose escalation and expansion stages to identify the maximum tolerated dose and assess safety and clinical activity.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In